11.00

0.00% 0.00

Cadrenal Therapeutics Inc (CVKD)

Overview News Price History Financials Discussions Forecast

Cadrenal Therapeutics Inc stock is traded at $11.00, with a volume of 105.00K. It is up +0.00% in the last 24 hours and down -10.13% over the past month. Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Previous Close:

$11.00

Open:

$11.34

24h Volume:

105.00K

Relative Volume:

3.42

Market Cap:

$22.83M

Revenue:

Net Income/Loss:

$-4.85M

P/E Ratio:

-35.48

EPS:

-0.31

Net Cash Flow:

$-3.95M

1W Performance:

+8.06%

1M Performance:

-10.13%

6M Performance:

-26.62%

1Y Performance:

-5.17%

1-Day Range:

$10.83

$11.44

1-Week Range:

$9.55

$12.00

52-Week Range:

$8.12

$22.90

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name

Cadrenal Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

904-300-0701

Address

822 A1A NORTH, PONTE VEDRA

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CVKD's Discussions on Twitter

Compare CVKD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CVKD Cadrenal Therapeutics Inc	11.00	22.83M	0	-4.85M	-3.95M	-0.31
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform

Cadrenal Therapeutics Inc Stock (CVKD) Latest News

02:52 AM

Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN

02:52 AM

Dec 12, 2025

Cadrenal's Quiet Expansion Play Is Starting to Get Loud - The Joplin Globe

Dec 12, 2025

Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan

Dec 12, 2025

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - ACCESS Newswire

Dec 12, 2025

Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan

Dec 12, 2025

Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals

Dec 12, 2025

Dec 11, 2025

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks

Dec 11, 2025

Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks

Dec 11, 2025

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Canada

Dec 11, 2025

Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com

Dec 11, 2025

Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan

Dec 11, 2025

Dec 06, 2025

Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga

Dec 06, 2025

Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn

Dec 06, 2025

Dec 05, 2025

Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser

Dec 05, 2025

Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser

Dec 05, 2025

Dec 03, 2025

The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com

Dec 03, 2025

Dec 02, 2025

Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser

Dec 02, 2025